Analyst Research Report Snapshot

Title:

Aurobindo Pharma (ARBP) - Qtr. Update - Dated - February 07, 2014

Price:

$35.00

Provider:

Axis Capital Limited

Date:

08 Feb 2014

Pages:

4

Type:

AcrobatPDF

Companies referenced:

ARBN.NS

Available for Immediate Download
Summary:

Aurobindo’s (Bloomberg: ARBP IN) Q3 performance was much ahead of estimates led by higher contribution from gCymbalta. Revenue grew 36% to Rs 21 bn vs. estimates (our: Rs 20 bn; Street: Rs 19 bn). Ex-gCymbalta EBITDA margin (assuming USD 28 mn revenue; 85% margin), was ~25% (23% in Q2; estimated 23%). Consequently, adjusted PAT of Rs 4.2 bn (1.5x Q3FY13) was above estimate (our/ Street: Rs 2.9 bn/ Rs 2.5 bn). Maintain HOLD; turnaround in EU acquisition key to re-rating (7% downside from CMP) We raise FY14E/ FY15E EPS by 22%/ 14% to Rs 40/ Rs 43 to factor in better margin. We maintain our target PE as we expect turnaround in Actavis business to be slow; faster turnaround/ lower margin impact may trigger rerating. Maintain HOLD with revised TP of Rs 470 (11x FY15E EPS) vs. Rs 411 earlier. At CMP of Rs 507, the stock trades at 13x FY14E EPS and 12x FY15E EPS. Key highlights  Revenue growth led by: (a) US (Rs 9 bn, up 81% YoY driven by currency benefits, USD 10 mn revenue from injectables, re-launch of Cephalosporins, and ramp-up of recent launches including gCymbalta), and (b) EU (up 37% YoY driven by customer addition and product launches). API revenue was up 13% YoY at Rs 7.4 bn  Gross margin improved ~800 bps YoY/ 600 bps QoQ to 58% largely due to gCymbalta. Ex-gCymbalta, gross margin was ~55% (assuming 90% gross margin on gCymbalta)  ARBP filed 14 ANDAs (308 cumulative) and received 6 final approvals in Q3FY14  US gaining traction: US growth was driven partially by re-introduction of Cephalosporin and ramp-up of injectable products (USD 10 mn in Q3; two products launched at Q3-end to drive growth in Q4) and largely by gCymbalta and few other launches. The company launched two more Controlled Substances in Q3. Management is confident of 20%+ growth in FY15. FY16 growth would be driven by launch of injectables under shortage list Regards, Deepak Khetan (VP – Life Sciences) Institutional Equity Research Axis Capital Limited Tel: +91 22 4325 1132

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.